Hepatitis

The Pharmacy Times® Hepatitis resource center provides clinical news and articles, pertaining to the Food and Drug Administration approved therapies to treat Hepatitis A, B, and C. Additionally, pharmacists will find coverage from pertinent conferences and meetings, videos, podcasts, and other associated content.

What can we help you find?
[[thumbnail_alt_text]]
This drug was previously approved, in 2017, to treat HCV in adults.
[[thumbnail_alt_text]]
Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
[[thumbnail_alt_text]]
HIV infection is associated with higher rates of hepatitis C replication.
[[thumbnail_alt_text]]
An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.
[[thumbnail_alt_text]]
Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.
[[thumbnail_alt_text]]
Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.
[[thumbnail_alt_text]]
A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.
[[thumbnail_alt_text]]
Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.
[[thumbnail_alt_text]]
The study was the first to compare patients with hepatitis C treated with direct-acting antiviral drugs and those untreated for long-term risks.
[[thumbnail_alt_text]]
Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.
[[thumbnail_alt_text]]
Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.
[[thumbnail_alt_text]]
New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.